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Clinical question — What is the
chance of developing multiple
sclerosis following the first episode of
optic neuritis in a 19-year-old male?
This question was asked of us at the
Centre for General Practice, University of
Queensland, Australia, where we were
providing a literature-search service in
collaboration with the Department of
Primary Health Care at the University of
Newcastle, funded through the NHS
Northern and Yorkshire Regional Library
Advisory Service, for local GPs. The
service was based on an Australian
model.1
We present our response to one of the
questions asked, updating the original
search July 2005.
SEARCH QUESTION
First, the clinical question was
reformatted into a ‘searchable question’.2
What is the risk of developing
clinically apparent multiple
sclerosis following a first episode
of optic neuritis in a young male?
The ideal study to answer this question
would be an inception cohort study of
adults experiencing a first episode of
optic neuritis over several years, with
minimal loss to follow-up, and the
development of clinically apparent
multiple sclerosis as the outcome.
RAPID SEARCH
We searched Medline (on SilverPlatter via
WebSpirs) for articles published in
English using the following terms ‘optic
neuritis’ (MeSH and text) AND ‘multiple
sclerosis’ (MeSH and text) combined with
a sensitive search filter for detecting
clinically sound prognostic studies.3
SUMMARY OF FINDINGS
There were many studies evaluating the
risk of developing multiple sclerosis after
a single episode of optic neuritis.4–13 Their
quality was good, although there may
have been differential measurement
causing bias (people with positive brain
MRIs may have been less likely to have
been lost to follow up, for example). 
The risk of developing multiple
sclerosis after an episode of optic neuritis
ranged from 13 to 58%. Even with brain
lesions identified at baseline, only slightly
more than half of patients later developed
clinical multiple sclerosis, although their
absence did not eliminate the risk
(0–22%).
Abnormal brain MRI were a strong
predictor of multiple sclerosis in the
largest study (optic neuritis trial), with
87% complete follow-up, the presence of
one or more white matter lesions on
baseline MRI brain scan more than
doubled the 10-year risk of multiple
sclerosis.4
COMMENT
The variation in results may be
attributable to differences in study
design, variation in criteria for the
diagnosis of multiple sclerosis and optic
neuritis, and length of follow-up. The
studies give a reasonably robust
indication of the prognosis. 
The prognosis seems to be better than
expected, and raises questions about
whether optic neuritis may have other
causes than the demyelination of multiple
sclerosis, or that multiple sclerosis has a
wide spectrum of expression, often little
or never interfering with patients’ lives.14
APPLYING THE RESULTS TO
THE PATIENT
Apart from offering an overall prognosis,
the literature suggests that this can be
improved on by testing with MRI for other
lesions on diagnosis of optic neuritis. 
It also raises the question of treatment.
The CHAMPS trial compared interferon
β–1a and placebo on developing multiple
sclerosis after a single demyelinating
event among 192 patients.15 After 3 years,
the adjusted rate ratios of clinically
definite multiple sclerosis between the
two trial arms was 0.58, (95% CI = 0.34 to
1.00). Similarly, in a second randomised
placebo controlled trial of interferon
≤β–1a among 309 patients with a first
neurologic episode consistent with
multiple sclerosis (although in only 35%
was this from optic neuritis), clinically
apparent multiple sclerosis developed in
34% intervention patients compared with
45% controls.16 But this is a different
question …
Sharon Sanders
Chris Del Mar
Sarah Purdy
Annelise Spinks
Lisa Tait
Brian McAvoy
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It is difficult to think of a greater
absurdity than the concept of a ‘patient-
led NHS’, the slogan that now guides
government health policy in Britain. 
Patients tend to be ill, and have
always therefore been provided with
care and attention and relieved of the
burdens of everyday life. They are not
expected to play a leading role in their
own treatment, never mind in leading the
NHS. Patients also tend to lack the
knowledge and expertise required to
play a leading role in NHS
administration, even in their own medical
management. When patients cease to
be patients they generally have little
interest in leading the NHS, having jobs
to do, families to look after, lives to lead. 
Those few patients who express a
great interest in running the NHS tend to
lack these other interests. Hence, they
are highly unrepresentative of patients in
general and, while giving them a greater
say in the direction of the NHS may
advance their exclusive concerns, it is
unlikely to prove beneficial to the vast
majority of patients. In my view, patients
expect competent care from a doctor-
led NHS, within a policy and funding
framework decided by a democratically
accountable government. I can think of
numerous innovations in health care
over the past 50 years — from special
care baby units to hospices for the
terminally ill — that were introduced on
the initiative of medical and nursing staff.
Although it is difficult to think of any
useful innovation that has resulted from
either political or consumer intervention,
numerous useless and wasteful
initiatives, from NHS Direct to ‘choose
and book’ come readily to mind.
But according to NHS chief executive
Nigel Crisp, we must abandon the
hopelessly old-fashioned concept of a
‘patient-centred NHS’.1 He believes that
in the modernised Britain we now have
the ‘capability as well as the capacity to
become truly patient-led and deliver
high quality services everywhere and at
all times’. But if services were universally
excellent, there would be no capacity for
improvement, even if staff had the
capability — under patient leadership, of
course — to achieve this.
The Department of Health has
struggled to explain its revolutionary
concept. Back in March it indicated that
‘a patient-led NHS means that patients
are supported to make choices about,
and take control of, their health and
health care, and services evolve to
provide personalised care by listening
and responding to patients.’2 It is difficult
to see any relationship at all between the
first and second half of this sentence. It
suggests, on the one hand, a
government-led NHS in which patients
are guided towards officially approved
life styles and behaviour, and, on the
other, an NHS that provides services
according to consumer demand.
In October, perhaps in response to
bemused patients, perhaps in an
attempt to resolve its own confusion, the
Department of Health again asked itself
the question: ‘What does patient-led
mean’? Its answer: it means ‘reshaping
how the service delivers care, based on
what patients need and want’.3 The
same ambivalence persists: the
government knows what patients need,
but who knows what they want? To find
out, the health minister commissioned a
PR firm to stage a consultation exercise,
featuring the showcase event attended
by health secretary Patricia Hewitt and
around 1000 carefully selected
members of the public (paid generous
expenses for the day).
Early reports indicated that three
proposals topped a poll of options for
reform: extending GP opening hours,
annual health MOTs and more walk-in
centres.4 This familiar list of the
preoccupations of the professional
middle classes confirms the way in
which this focus-group approach places
the demands of the worried well over
those of the seriously ill (or even of the
not very well, but socially marginal). The
true purpose of a ‘patient-led NHS’
emerges as the subordination of the
NHS to the political and electoral
requirements of New Labour. Can a
lunatic-led asylum be far behind?
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A patient-led NHS?
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